跳至主要内容

PARP Inhibitors In Stock!

Poly(ADP-ribose) polymerases (PARP) are enzymes involved in DNA-damage repair. DNA is damaged thousands of times during each cell cycle, and that damage must be repaired. BRCA1, BRCA2 and PALB2 are proteins that are important for the repair of double-strand DNA breaks by the error-free homologous recombinational repair, or HRR, pathway. When the gene for either protein is mutated, the change can lead to errors in DNA repair that can eventually cause breast cancer. When subjected to enough damage at one time, the altered gene can cause the death of the cells. Inhibition of PARPs is a promising strategy for targeting cancers with defective DNA-damage repair, including BRCA1 and BRCA2 mutation-associated breast and ovarian cancers. Several PARP inhibitors are currently in trials in the adjuvant, neoadjuvant, and metastatic settings for the treatment of ovarian, BRCA-mutated breast, and other cancers.
Co-Crystal structure of PARP-1 and one of it’s inhibitors
CAS 1038915-60-4
Cat No.:I000230
Cas No.:1038915-60-4
Product Name:MK-4827
CAS 1038915-64-8
Cat No.:I000231
Cas No.:1038915-64-8
Product Name:MK-4827 hydrochloride
CAS 1038915-73-9
Cat No.:I000232
Cas No.:1038915-73-9
Product Name:MK-4827 tosylate
CAS 1048371-03-4
Cat No.:I000270
Cas No.:1048371-03-4
Product Name:UPF 1069
CAS 1140964-99-3
Cat No.:I000532
Cas No.:1140964-99-3
Product Name:E7449
CAS 1174043-16-3
Cat No.:I000622
Cas No.:1174043-16-3
Product Name:AZD-2461
CAS 1207456-00-5
Cat No.:I000775
Cas No.:1207456-00-5
Product Name:BMN-673 8R,9S
CAS 1207456-01-6
Cat No.:I000776
Cas No.:1207456-01-6
Product Name:BMN-673
CAS 1262417-51-5
Cat No.:I001056
Cas No.:1262417-51-5
Product Name:NMS-P118
CAS 160003-66-7
Cat No.:I002034
Cas No.:160003-66-7
Product Name:BSI-201
CAS 283173-50-2
Cat No.:I002961
Cas No.:283173-50-2
Product Name:Rucaparib
CAS 328543-09-5
Cat No.:I003166
Cas No.:328543-09-5
Product Name:AG14361
CAS 344458-15-7
Cat No.:I003256
Cas No.:344458-15-7
Product Name:PJ34 hydrochloride
CAS 344458-19-1
Cat No.:I003257
Cas No.:344458-19-1
Product Name:PJ34
CAS 3544-24-9
Cat No.:I003291
Cas No.:3544-24-9
Product Name:INO-1001
CAS 459868-92-9
Cat No.:I003606
Cas No.:459868-92-9
Product Name:Rucaparib phosphate
CAS 664993-53-7
Cat No.:I004499
Cas No.:664993-53-7
Product Name:JW 55
CAS 66611-37-8
Cat No.:I004506
Cas No.:66611-37-8
Product Name:BGP-15
CAS 763113-22-0
Cat No.:I004823
Cas No.:763113-22-0
Product Name:Olaparib
CAS 912444-00-9
Cat No.:I005438
Cas No.:912444-00-9
Product Name:Veliparib
CAS 912445-05-7
Cat No.:I005439
Cas No.:912445-05-7
Product Name:Veliparib dihydrochloride
CAS 934162-61-5
Cat No.:I005541
Cas No.:934162-61-5
Product Name:A-966492

评论

此博客中的热门博文

A major introduction to BYL-719!

BYL719(cas 1217486-61-7) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM, liitle or no effect on PI3Kβ/γ/δ. BYL719 inhibits the proliferation of breast cancer cell lines harboring PIK3CA mutations, correlating with inhibition of various downstream signaling components of the PI3K/Akt pathway.

PIM447

PIM447(cas 1210608-43-7) is novel pan-PIM kinase inhibitor, including Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase. PIM447 is cytotoxic for myeloma cells due to cell cycle disruption and induction of apoptosis mediated by a decrease in phospho-Bad (Ser112) and c-Myc levels and the inhibition of mTORC1 pathway. PIM447 also inhibits in vitro osteoclast formation and resorption, downregulates key molecules involved in these processes and partially disrupts the F-actin ring, while increasing osteoblast activity and mineralization.

A major introduction to T-705!

Favipiravir (cas 259793-96-9 ), also known as T-705 or Avigan, is an antiviral drug that selectively inhibits the RNA-dependent RNA polymerase of influenza virus. It is phosphoribosylated by cellular enzymes to its active form, favipiravir-ribofuranosyl-5'-triphosphate (RTP). Favipiravir is active against a broad range of influenza viruses, including A(H1N1)pdm09, A(H5N1) and the recently emerged A(H7N9) avian virus. It also inhibits influenza strains resistant to current antiviral drugs, and shows a synergistic effect in combination with oseltamivir, thereby expanding influenza treatment options.